WCLC | Conference

Roy S. Herbst, MD, PhD, on What Multidisciplinary Providers Should Know About KEYNOTE-010
February 26, 2021

The KEYNOTE-010 study evaluated the use of either pembrolizumab or docetaxel in patients with previously treated, PD-L1–positive advanced non–small cell lung cancer.

Salma Jabbour, MD, on Next Steps for the KEYNOTE-799 Study
February 24, 2021

The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed how she hopes the results of the KEYNOTE-799 study will impact testing going forward.

Salma Jabbour, MD, on AEs Observed With Pembrolizumab Plus Concurrent Chemoradiotherapy in Stage III NSCLC
February 23, 2021

The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed the adverse events associated with the use of pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non–small cell lung cancer.